Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CD22 (Epratuzumab Biosimilar) antibody

Reactivity: Cynomolgus, Human, Rhesus Monkey BP, FACS, IP Host: Human Monoclonal hL22 unconjugated Recombinant Antibody
Catalog No. ABIN5668216
  • Target See all CD22 (Epratuzumab Biosimilar) products
    CD22 (Epratuzumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Cynomolgus, Human, Rhesus Monkey
    Host
    • 1
    Human
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
    Application
    Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)
    Specificity
    This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
    Characteristics

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Purified antibody.
    Purity
    > 98 % as determined by SDS-PAGE
    Endotoxin Level
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogen
    This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
    Clone
    HL22
    Isotype
    IgG1 kappa
  • Application Notes
    Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
    Restrictions
    For Research Use only
  • Buffer
    PBS with 0.02 % Proclin 300.
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    CD22 (Epratuzumab Biosimilar)
    Abstract
    CD22 (Epratuzumab Biosimilar) Products
    Synonyms
    SIGLEC-2 antibody, SIGLEC2 antibody, CD22 molecule antibody, CD22 antibody
    Target Type
    Biosimilar
    Background
    Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
    UniProt
    P20273
You are here:
Support